Hot Products
Hot products from BioCrick which is a professional high-purity natural products manufacturer are well known to scientists around the world because of their high purity and stability. Each product is a chemical compound or substance produced by a living organism—that is, found in nature. In the broadest sense, natural products include any substance produced by life.Natural products remain the best sources of drugs and drug leads, and this remains true today despite the fact that many pharmaceutical companies have deemphasized natural products research in favor of HTP screening of combinatorial libraries during the past 2 decades. From 1940s to date, 131 (74.8%) out of 175 small molecule anticancer drugs are natural product-based/inspired, with 85 (48.6%) being either natural products or derived therefrom. From 1981 to date, 79 (80%) out of 99 small molecule anticancer drugs are natural product-based/inspired, with 53 (53%) being either natural products or derived therefrom. Among the 20 approved small molecule New Chemical Entities (NCEs) in 2010, a half of them are natural products.
Hot products from the professional high-purity natural products manufacturer
| Cat.No. | Product Name |
|---|---|
| BCC7672 | EIPA |
| TRPP3 channel inhibitor (IC50 = 10.5 μM). Inhibits the Na+/H+ exchanger (NHE). Derivative of amiloride. | |
| BCC7673 | Phenamil |
| TRPP3 channel inhibitor (IC50 = 0.14 μM). Also inhibits epithelial Na+ channels (Kd = 0.4 nM for a high affinity site on the epithelial Na+ channel). Derivative of amiloride. | |
| BCC7674 | Benzamil |
| Na+/Ca2+ exhanger (NCX) inhibitor (IC50 ~ 100 nM); TRPP3 channel blocker (IC50 = 1.1 μM for inhibition of Ca2+-activated TRPP3 channel activity). Also non-selective Deg/ENaC family blocker; reduces mechanosensitivity of colonic afferents. More potent derivative of amiloride. | |
| BCC7675 | AM 1172 |
| Metabolically stable anandamide uptake inhibitor (IC50 = 2.1 - 2.5 μM) and fatty acid amide hydrolase (FAAH) inhibitor (Ki = 3.18 μM). Inhibits N-arachidonylethanolamine (AEA) accumulation (IC50 = 24 μM) and hydrolysis (Ki = 3 μM), and inhibits N-palmitoylethanolamine (PEA) hydrolysis (IC50 = 36 μM) in cerebellar granule neurons. Also acts as a non-selective cannabinoid receptor partial agonist (EC50 values are 189 and 271 nM at CB2 and CB1 receptors respectively). | |
| BCC7676 | Gedunin |
| Naturally occurring Hsp90 inhibitor. Induces Hsp90-dependent client protein degradation and displays antiproliferative activity in vitro (IC50 values are 3.22, 8.84 and 16.8 μM in SKBr3, MCF-7 and CaCo-2 cancer cell lines respectively). Also exhibits antimalarial activity against P. falciparum (IC50 values are 0.14 and 3.1 μM in parasite development and [3H]-hypoxanthine uptake assays respectively). | |
| BCC7678 | S 32826 |
| Inhibitor of autotaxin (IC50 = 9 nM). Displays similar inhibitory effects at all three autotaxin isoforms (α, β and γ). Exhibits no affinity for lysophosphatidic acid receptor 1 (LPA1) at concentrations up to 10 μM. Inhibits LPA release from adipocytes (IC50 = 90 nM). | |
| BCC7679 | BMS 453 |
| Synthetic retinoid. Retinoic acid receptor β (RARβ) agonist in vivo; RARα and RARγ antagonist in vitro. Inhibits breast cell proliferation by inducing active transforming growth factor β (TGFβ) and causes G1 arrest. | |
| BCC7680 | BMS 961 |
| Selective RARγ agonist (EC50 values are 30 and 1000 nM at RARγ and RARβ respectively). Displays no activity at RARα receptors. | |
